Recombinant Fviii Fc Fusion Product Eloctate
Menstrual Flow Excessive
Emory UniversityEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Menstrual Flow Excessive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selmevit Tyumen State Medical Academy | Phase 4 | BB |
Doxycycline University of Rochester | Phase 3 | B |
Cyclobenzaprine Christiana Care Health Services | Phase 4 | B |
Recombinant Fix Fc Fusion Product Alprolix Emory University | Early Phase 1 | CC |
Inositol University of Bari Aldo Moro | N/A | D |
Folic Acid Catholic University of the Sacred Heart | N/A | D |
Same molecule, other indications
Recombinant Fviii Fc Fusion Product Eloctate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →